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Translate, culturally adapt, and validate the “Parkinson’s Disease Quality of Life” (PDQL) BR, into Brazilian Portuguese. Fifty-two
patients answered the PDQL-BR. Twenty-one patients answered the PDQL-BR again 14 days later. The UPDRS and HY scale was
applied. Validation was evaluated using psychometric properties, checking the quality of the data, reliability, and validity. Quality
of the data was evaluated based on occurrence of ceiling and ﬂoor eﬀects. Reliability was evaluated based on: internal consistency
of an item, homogeneity, and reproducibility. Validation was checked through the evaluation of convergent and discriminatory
validation. There was no ceiling and ﬂoor eﬀect. When evaluating reliability, items 20, 30, and 37 showed correlation of 0.34, 0.26,
and 0.37, respectively, to your scale; the other items was higher than 0.4. The alpha Cronbach coeﬃcient was higher than 0.7 for
most domains. There was good reproducibility. There were no meaningful changes in the PDQL-BR translation and cross-cultural
adaptation.
1.Introduction
Parkinson’s disease (PD) is a neurodegenerative disease char-
acterized by the occurrence of motor and nonmotor symp-
toms. Motor symptoms include arrest tremors, stiﬀness,
bradykinesia,andinstabilitiesinpostureandgait.Nonmotor
symptoms include autonomic dysfunctions that result in
changes in blood pressure control and intestinal function.
The disease shows an inevitably progressive course and an
increasing number of other symptoms. Frequently, Parkin-
son’s disease patients go through periods of depression and
dementia. In more advanced stages, complications caused
by treatment with dopaminergic drugs result in ﬂuctuations
in motor function [1]. The symptoms, comorbidities, and
complications of treatment restrict the autonomy and the
welfare of aﬀected individuals, leading to prejudices in their
professional, social, and emotional lives [2].
In order to evaluate multidimensional features such as
those described above, recently special attention has been
given to evaluating the quality of life (QL) and, more
specifically the perception of welfare in light of the state of
the patient health, which has lead to the development of
the Health-Related Quality of Life (HRQL) surveys [3]. The
development of the HRQL has allowed health care providers
to determine a better approach to caring for the patient; the
HRQL also places more value on considering the needs and
the expectations of the patient and provides a comparison
among diﬀerent groups [3]. The HRQL instruments are
divided into two groups: generic and speciﬁc. The generic
instruments determine general features of health and have
advantages, such as wide applicability, that allow them to be
used in diﬀerent groups of patients and allowing compari-
sons among the groups. The speciﬁc surveys may be used
in speciﬁc situations, such as PD, and their advantage is an2 ISRN Neurology
approach to speciﬁc aspects of the disease being studied,
allowing the comparison of individuals in the same group
[4].
FourinstrumentsofHRQLhavebeendeveloped andval-
idated speciﬁcally for PD: Parkinson’s Disease Questionnaire
39 (PDQ-39), Parkinson’s disease quality of life (PDQL),
Parkinson’s Impact Scale (PIMS), and Parkinson’s Lebens
Qualitat (PLQ). Among them, the PDQ-39 is considered
the most appropriate; however, it has shortcomings in the
evaluation of self-image sleep disturbance and sexuality of
patients. Because the PDQL takes into account these prob-
lems, it has become an alternative to PDQ-39 [5]. For these
reasons, the PDQL has generated more interest, and there
hasbeenanincreaseintranslationandvalidationsforseveral
languages and cultures [5].
The simple translation of HRQL instruments into the
language of countries or cultures diﬀerent from the ones in
which they were developed is insuﬃcient, because the in-
ﬂuence of culture and linguistics may necessitate conceptual
changes [6, 7]. While there is no universal agreement about
how these instruments must be translated and culturally
adapted, back translation is thought to be the most appro-
priate mechanism. After translation and cross-cultural adap-
tation, the instrument should be validated in order to deter-
mine if the translation process changed the psychometric
properties of the original instrument [7]. The aim of this




Committee of the Federal University of Uberlandia (UFU).
All of the patients agreed to participate in the study (consent
term). The use of the PDQL is in accordance with the norms
of use of MAPI Trust Research [8].
2.2. Instrument. Following the international recommenda-
tions for translation and cross-cultural adaptation [6–8], the
original instrument was initially translated into Brazilian
Portuguese by two English language teachers that were born
inBrazilandareﬂuentintheEnglishlanguage.Bothversions
were compared by a neurology professor who is a Brazilian
native and who consolidated the ﬁrst version. This version
was then translated into the original language (backtrans-
lation) [7] by an English language teacher from the United
Kingdom who is ﬂuent in Brazilian Portuguese. This version
was compared to the original version before being accepted
for cultural adaptation. For cultural adaptation, the instru-
ment was applied given to a group of patients with PD in
order to consolidate the ﬁnal version to be validated, the
PDQL-BR.
The PDQL-BR, like the original, is composed of thirty-
seven items divided into four domains: parkinsonian symp-
toms (14 items), systemic symptoms (9 items), emotional
function (7 items), and social function (7 items). Each item
is scored from 1 to 5, and the total score of the instrument
is given by the sum of the averages of the scores from
each domain. Higher scores represent a better perception of
HRQL by the patient [9].
2.3. Patients. A convenience sample, composed of patients
diagnosed with PD according to the UK Parkinson’s Disease
Society brain bank criteria, came from the movement
disturbancesambulatoryclinicoftheUFU,theassociationof
patients with parkinson’s disease in Uberlandia, and private
neurology clinics. Patients that were unable to participate in
everyday activities due to comorbidities other than PD and
patients with serious cognitive damage who scored less than
eighteen points on the Miniexam for mental state [10]w e r e
excluded from the study.
2.4. Procedures. All of the patients went through a clinical
evaluationbyaneurologist.Thediseasewasstagedaccording
to the modiﬁed classiﬁcation of Hoehn and Yahr (HY) [11]
and then patients were classiﬁed into phases. The initial
phase was composed of HY stages 1.0, 1.5, and 2.0, the mod-
erate phase HY stage 2.5, and the advanced phase HY stages
3.0, 4.0, and 5.0. A global evaluation of functional damage
was done for each patient using the Uniﬁed Parkinson’s
Disease Rating Scale(UPDRS)[12]. After clinical evaluation,
thepatientsansweredasocial-demographicquestionnaireby
interview, the PDQL-BR and the Beck Depression Inventory
(BDI) [13] ,a n dw e r ei n v i t e dt or e t u r nw i t h i n1 4d a y st o
answer the PDQL-BR again.
2.5.Validation. ThePDQL-BRwasvalidatedbycheckingthe
psychometric properties of the instrument and the quality of
the data; reliability and validity were analyzed. The quality of
the data was veriﬁed by checking the occurrence of ﬂoor and
ceiling eﬀects and the percentage of lost data. The presence
of ﬂoor or ceiling eﬀects indicates that the instrument has
diﬃculty detecting diﬀerences in the perception of welfare
among individuals with the lowest possible score (ﬂoor ef-
fect) or with the highest possible score (ceiling eﬀect). Lost
data are data which could not be used in the evaluation and
interpretationoftheapplicationoftheinstrument,andaloss
of less than 10% of the data obtained was considered reason-
able [14].
The reliability of the instrument was evaluated by deter-
mining the internal consistency of the item, the reliability
of the internal consistency, and reproducibility. The internal
consistency of an item evaluates the ability of each item to
contribute to the creation of a basis for the scale that it
represents [15]. It was determined by correlating each item
to its domain and evaluating the percentage of items that
correlate in a satisfactory way to their domain (success rate)
[14]. The reliability of the internal consistency or homoge-
neity of data of a domain or scale is the extent to which all
of their data deﬁne diﬀerent aspects of the same attribute
[15]. The reliability of internal consistency is guaranteed
when the items are moderately correlated to each other and
when each item correlates to the total score [15]. Reliability
was calculated for each domain and for the PDQL-BR.
Reproducibility is the capacity of the instrument, in stable
conditions, to reproduce the same results obtained from anISRN Neurology 3
initial evaluation [15]. Reapplication of PDQL-BR occurred
within a period of 14 days after the ﬁrst test.
Validity determines if the tool really measures the con-
cepts it is supposed to measure, and that it does not measure
what it isn’t intended to measure [16]. Discriminatory
validityandconvergentvaliditywerestudied.Discriminatory
validity veriﬁes the capacity of the instrument to discrim-
inate among subgroups of patients in diﬀerent clinical
states [9] and was determined by comparing the PDQL-
BR scores and the parkinsonian symptoms domain and the
systemic symptoms among the groups of patients in initial,
moderate, and advanced phases of the disease. Convergent
validity determines the amount of association between two
measures of the same construct [9]. It was determined by
correlating scores from the parkinsonian symptoms domain
of the PDQL-BR and scores of the UPDRS III and among
emotional function scores from the PDQL-BR and UPDRS I
and the BDI scores.
2.6. Statistics. Descriptive statistics were used for the charac-
terization of the sample. For correlation tests, the Spearman
correlation coeﬃcient was used because it is considered a
satisfactorycorrelation when it is over 0.4. For the evaluation
of internal consistency of an item, the success rate was
considered satisfactory when it was greater than 80%. For
the reliability evaluation of internal consistency, the alpha-
Cronbach coeﬃcient was used, and values over 0.7 were
considered satisfactory internal consistency for comparison
among groups. For the evaluation of reproducibility of the
instrument and discriminatory validity, the Mann-Whitney
test was used. The level considered signiﬁcant was P<0.05.
3. Results
3.1.Instrument. Duringtheprocessofcross-culturaladapta-
tion, item 20 of the scale referred to “per´ ıodos de liga/desliga”
was modiﬁed to “per´ ı o d o sd et r a v a / d e s t r a v a(momentos
com/sem ac ¸˜ ao dos rem´ edios)” to improve the understanding
of the phase.
3.2. Patients. Fifty-eight patients were invited to participate
in the study. Five were excluded because they had cognitive
damage, and one did not ﬁt the criteria for diagnosis of PD.
Thirty-six (69.2%) were male. The patients’ ages varied from
37 to 88 years (average: 64.83 PD 11.81). Forty-ﬁve (86.5%)
ofthepatientswereCaucasian,and33(63.5%)weremarried.
The clinical characteristics are presented in Table 1.
3.3. Validation
3.3.1. Quality of Data. Floor and ceiling eﬀects were not
observed for any of the PDQLBR domains, and the rate of
lost data varied among domains from 0.3 to 0.6%.
3.3.2. Reliability. For internal consistency of items, all of the
items in both the systemic symptoms and social function
domains had correlations greater than 0.4 with their re-
spective scales (success rate of 100%). In the parkinsonian
Table 1: Clinical characteristics of patients.
Clinical characteristics (N)( % )
Duration of illness
Up to 5 years 25 48.1
F r o m6t o1 0y e a r s 1 3 2 5 . 0
More than 10 years 13 25.0
Unknown 1 1.9
Staging
Initial phase (HY 1/1.5/2) 8 15.3
Moderate phase (HY 2.5) 23 44.2
Advanced phase (HY 3/4/5) 21 40.4
symptoms domain, the items 20 and 30 had correlations of
0.34 and 0.26, respectively, but the other items had correla-
tions that were greater than 0.4 (success rate of 85.71%). In
the emotional function domain, item 37 had a correlation of
0.37. The other items had correlations that were greater than
0.4 (success rate of 88.89%). For evaluation of the reliability
of internal consistency, the alpha Cronbach coeﬃcient of
the tool and for each domain was higher than 0.65 and
can be seen in Table 2. Twenty-one patients answered the
PDQLBR again for the evaluation of reproducibility. The
second occurrence was fourteen days after the ﬁrst applica-
tion of the instrument. There were no statistically signiﬁcant
differences between the average scores of the two PDQL-BR
applications.
3.3.3.Validity. In the evaluation of discriminatory validity of
the PDQL-BR, the parkinsonian symptoms and the systemic
symptoms scores showed diﬀerences among all the phases of
the disease because the average scores of the patients in each
phase diﬀered, with lower scores as the disease advanced. For
convergent validity, correlation between the parkinsonian
symptoms domain of the PDQL-BR and UPDRS III was
0.78. For the emotional function domain of the PDQL-BR,
correlations with the UPDRS I and the DBI were 0.59 and
0.57, respectively, with signiﬁcance level of 0.01.
4. Discussion
The clinical characteristics of the evaluated patients were
similar to the characteristics observed in other studies of
translations and validation of PDQL. The population of the
study was similar with regard to the evolution of the disease
[17–19]. The data obtained were satisfactory for analysis.
The data collection by interview minimized the loss of data,
and the absence of ﬂoor or ceiling eﬀects indicated that,
according to theory, the translated version of the instru-
ment kept its capacity to determine changes. It is possible
that the patients did not have a good understanding of
item 20 “per´ ıodos de trava/destrava (momentos com/sem
ac ¸˜ ao dos rem´ edios),” because this item had been translated
as “per´ ıodos liga/desliga” in the translation process and then
had generated incapacity of understanding by the patients.
Even after a change in the translation, it is possible that4 ISRN Neurology
Table 2: Comparison of the alpha-Cronbach coeﬃcients among studies.
De Boer et al. [9]H o b s o n e t a l . [ 2] Serrano-Due˜ nas et al. [19] Present study
PDQL 0.94 0.95 0.92 0.93
Parkinsonian symptoms 0.86 0.87 0.85 0.83
Systemic symptoms 0.80 0.77 0.69 0.65
Emotional function 0.87 0.87 0.78 0.79
Social function 0.82 0.85 0.81 0.80
patients still did not fully understand the symptom, causing
low correlation with the domain that it represents. However,
the low correlations of items 30 “movimentos repentinos
en ˜ ao controlados” and 37 “sente-se preocupado (a) com as
poss´ ıveis consequˆ encias de uma operac ¸˜ ao por causa de sua
doenc ¸a” are possibly associated with the inner characteristics
of the studied population. In the ﬁrst item, patients from
nonspecialized ambulatory clinics before the inclusion of
the disturbance movement ambulatory clinic of the Federal
University of Uberlandia were medicated with low doses of
levodopa and, consequently, had low frequencies of motor
ﬂuctuation, the symptom referred to in item 30. However,
they indicated that they had signiﬁcantly damage from the
disease due to the use of very low doses of levodopa. Item
37 does not depend on the clinical condition of the patient.
Surgical procedures for treatment of PD are not routinely
performed at the clinics from which the patients were
recruited, which may not mean anything for most patients.
Theinstrumentshoweditselftobereliable,becausethealpha
Cronbach coeﬃcient for most domains was higher than 0.7.
Onlyinthesystemicsymptomsdomainwasit0.65.However,
greatcorrelationwasobservedamongtheprincipalstudiesof
validation of the instrument in diﬀerent cultures, according
to Table 2.
The translated version of the instrument demonstrated
good reproducibility because there were no signiﬁcant
variationsinthescoresobtainedfromtheﬁrstandthesecond
application. For the validity evaluation, we observed that the
instrument had a good convergent validity and showed good
association between the parkinsonian symptoms domain
and the UPDRS III motor evaluation and also among the
emotional function domain and the evaluation for UPDRS
I and BDI scores. We also observed that the tool had a
good capacity to discriminate among patients in the initial,
moderate, and advanced stages.
5. Conclusions
We conclude that the translated version of PDQL (PDQL-
BR) did not undergo meaningful changes in the process
of translation and cross-cultural adaptation and keeps its
psychometric proprieties well preserved. A careful interpre-
tation of the evaluation of answers to items 20, 30, and 37 is
recommended.
The current study showed that PDQL-BR is a valid in-
strument for use in Brazil; however, the validation process is
dynamic and goes through changes over time. Only frequent
use of the instrument will result in more consistent theo-
retical evaluations. Thus, we understand that more studies
using the instrument will be fundamentally important for
increasing the knowledge of it.
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